PETER MUELLER Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for PETER MUELLER.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of PETER MUELLER. PETER MUELLER is EVP, Global R&D, CSO in VERTEX PHARMACEUTICALS INC / MA ($VRTX).
Latest Insider Trading Transactions of PETER MUELLER
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 28.84 | 7,500 | 216,300 | 24,250 | |
| Dec 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 65.42 | 2,100 | 137,382 | 141,500 | 143.6 K to 141.5 K (-1.46 %) |
| Dec 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 64.40 | 5,400 | 347,760 | 143,600 | 149 K to 143.6 K (-3.62 %) |
| Dec 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 28.84 | 7,500 | 216,300 | 149,000 | 141.5 K to 149 K (+5.30 %) |
| Dec 12 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 65.48 | 2,900 | 189,892 | 141,500 | 144.4 K to 141.5 K (-2.01 %) |
| Nov 19 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 28.84 | 4,500 | 129,780 | 31,750 | |
| Nov 19 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 18.93 | 3,000 | 56,790 | 0 | |
| Nov 19 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 63.12 | 2,200 | 138,864 | 144,400 | 146.6 K to 144.4 K (-1.50 %) |
| Nov 19 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 62.62 | 4,200 | 263,004 | 146,600 | 150.8 K to 146.6 K (-2.79 %) |
| Nov 19 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 61.58 | 1,100 | 67,738 | 150,800 | 151.9 K to 150.8 K (-0.72 %) |
| Nov 19 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 18.93 | 3,000 | 56,790 | 151,900 | 148.9 K to 151.9 K (+2.01 %) |
| Nov 19 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 28.84 | 4,500 | 129,780 | 148,900 | 144.4 K to 148.9 K (+3.12 %) |
| Oct 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 18.93 | 7,500 | 141,975 | 3,000 | |
| Oct 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 73.85 | 666 | 49,184 | 144,400 | 145.1 K to 144.4 K (-0.46 %) |
| Oct 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 73.19 | 6,834 | 500,180 | 145,066 | 151.9 K to 145.1 K (-4.50 %) |
| Oct 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 18.93 | 7,500 | 141,975 | 151,900 | 144.4 K to 151.9 K (+5.19 %) |
| Sep 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 18.93 | 7,500 | 141,975 | 10,500 | |
| Sep 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 79.08 | 200 | 15,816 | 144,400 | 144.6 K to 144.4 K (-0.14 %) |
| Sep 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 78.38 | 1,320 | 103,462 | 144,600 | 145.9 K to 144.6 K (-0.90 %) |
| Sep 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 77.44 | 2,895 | 224,189 | 145,920 | 148.8 K to 145.9 K (-1.95 %) |
| Sep 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 76.40 | 3,085 | 235,694 | 148,815 | 151.9 K to 148.8 K (-2.03 %) |
| Sep 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 18.93 | 7,500 | 141,975 | 151,900 | 144.4 K to 151.9 K (+5.19 %) |
| Aug 19 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 18.93 | 7,500 | 141,975 | 18,000 | |
| Aug 19 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 77.93 | 3,000 | 233,790 | 144,400 | 147.4 K to 144.4 K (-2.04 %) |
| Aug 19 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 77.06 | 4,500 | 346,770 | 147,400 | 151.9 K to 147.4 K (-2.96 %) |
| Aug 19 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 18.93 | 7,500 | 141,975 | 151,900 | 144.4 K to 151.9 K (+5.19 %) |
| Aug 01 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | A | 83.36 | 34,000 | 2,834,240 | 34,000 | |
| Jul 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 18.93 | 7,500 | 141,975 | 25,500 | |
| Jul 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 86.66 | 2,535 | 219,683 | 144,400 | 146.9 K to 144.4 K (-1.73 %) |
| Jul 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 86.17 | 4,965 | 427,834 | 146,935 | 151.9 K to 146.9 K (-3.27 %) |
| Jul 17 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 18.93 | 7,500 | 141,975 | 151,900 | 144.4 K to 151.9 K (+5.19 %) |
| Jul 03 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 18.93 | 7,500 | 141,975 | 33,000 | |
| Jul 03 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 16.32 | 9,800 | 159,936 | 0 | |
| Jul 03 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 33.00 | 105,000 | 3,465,000 | 195,000 | |
| Jul 03 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 80.58 | 39,365 | 3,172,032 | 144,400 | 183.8 K to 144.4 K (-21.42 %) |
| Jul 03 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 79.52 | 68,985 | 5,485,687 | 183,765 | 252.8 K to 183.8 K (-27.29 %) |
| Jul 03 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 78.94 | 13,950 | 1,101,213 | 252,750 | 266.7 K to 252.8 K (-5.23 %) |
| Jul 03 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 18.93 | 7,500 | 141,975 | 266,700 | 259.2 K to 266.7 K (+2.89 %) |
| Jul 03 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 16.32 | 9,800 | 159,936 | 259,200 | 249.4 K to 259.2 K (+3.93 %) |
| Jul 03 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 33.00 | 105,000 | 3,465,000 | 249,400 | 144.4 K to 249.4 K (+72.71 %) |
| May 20 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Gift | G | 0.00 | 10,352 | 0 | 0 | 10.4 K to 0 (-100.00 %) |
| Feb 07 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | A | 45.11 | 54,375 | 2,452,856 | 54,375 | |
| Feb 07 2013 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Grant | A | 0.01 | 12,084 | 121 | 144,400 | 132.3 K to 144.4 K (+9.13 %) |
| Oct 16 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 16.32 | 6,500 | 106,080 | 9,800 | |
| Oct 16 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 53.14 | 2,000 | 106,280 | 132,316 | 134.3 K to 132.3 K (-1.49 %) |
| Oct 16 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 52.83 | 4,500 | 237,735 | 134,316 | 138.8 K to 134.3 K (-3.24 %) |
| Oct 16 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 16.32 | 6,500 | 106,080 | 138,816 | 132.3 K to 138.8 K (+4.91 %) |
| Sep 19 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 16.32 | 6,500 | 106,080 | 16,300 | |
| Sep 19 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 57.52 | 6,500 | 373,880 | 132,316 | 138.8 K to 132.3 K (-4.68 %) |
| Sep 19 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 16.32 | 6,500 | 106,080 | 138,816 | 132.3 K to 138.8 K (+4.91 %) |
| Aug 17 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 16.32 | 6,500 | 106,080 | 22,800 | |
| Aug 17 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 54.30 | 4,100 | 222,630 | 132,316 | 136.4 K to 132.3 K (-3.01 %) |
| Aug 17 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 53.84 | 2,400 | 129,216 | 136,416 | 138.8 K to 136.4 K (-1.73 %) |
| Aug 17 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 16.32 | 6,500 | 106,080 | 138,816 | 132.3 K to 138.8 K (+4.91 %) |
| Jul 26 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | A | 48.74 | 36,250 | 1,766,825 | 36,250 | |
| Jul 18 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 16.32 | 6,500 | 106,080 | 29,300 | |
| Jul 18 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 53.24 | 2,500 | 133,100 | 132,316 | 134.8 K to 132.3 K (-1.85 %) |
| Jul 18 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 52.49 | 4,000 | 209,960 | 134,816 | 138.8 K to 134.8 K (-2.88 %) |
| Jul 18 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 16.32 | 6,500 | 106,080 | 138,816 | 132.3 K to 138.8 K (+4.91 %) |
| Jun 19 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Option Exercise | M | 16.32 | 6,500 | 106,080 | 35,800 | |
| Jun 19 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Sell | S | 56.37 | 6,500 | 366,405 | 132,316 | 138.8 K to 132.3 K (-4.68 %) |
| Jun 19 2012 | VRTX | VERTEX PHARMACEUTI ... | MUELLER PETER | EVP, Global R&D, CS ... | Buy | M | 16.32 | 6,500 | 106,080 | 138,816 | 132.3 K to 138.8 K (+4.91 %) |
Page: 1